pharmaphorum| News & views on pharma and biotech’s evolving future

Patients

Phyllis Arthur, Dr Larry Buchson, Sherri Berger, and Dr Luciana Borio discuss vaccine skepticism at BIO 2025.

Planning, not panic, as BIO weighs in on US vaccination woes

At BIO 2025, vaccines were top of mind as a result of recent actions by HHS. Speakers addressed news head on, but also explored the larger context.

R&D

Lady listening via ear pods to a podcast interview that features Melissa Sharman

Precision, speed, impact: Evolving mass spectrometry for med...

MOBILion's Melissa Sherman explores the evolving role of mass spectrometry in drug discovery, complex molecule analysis, and medical research.

Spotlight on

BIO International Convention

The annual conference of the Biotechnology Innovation Organization (BIO) is always an anticipated gathering where pharma and biotech leaders and policymakers meet to discuss the challenges facing their industry.

Digital

From pilots to impact: What it really takes to scale GenAI i...

Just a year ago, the GenAI buzz in pharma felt like the start of a gold rush. Leaders greenlit pilots. Teams spun up proof-of-concepts.

Oncology

ASCO 2025: Building a stronger future in cancer care with a ...

From attending key oral sessions, clinical science symposiums and poster presentations to the simple pleasures of chatting with colleagues during coffee breaks, we left the

Featured Content

Patients

Planning, not panic, as BIO weighs in on US vaccination woes

At BIO 2025, vaccines were top of mind as a result of recent actions by HHS. Speakers addressed news head on, but also explored the larger context.

Spotlight on

BIO International Convention

The annual conference of the Biotechnology Innovation Organization (BIO) is always an anticipated gathering where pharma and biotech leaders and policymakers meet to discuss the challenges facing their industry.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Market Access

Bridging research and clinical guidelines – interactive stra...

Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.

R&D

Precision, speed, impact: Evolving mass spectrometry for med...

MOBILion's Melissa Sherman explores the evolving role of mass spectrometry in drug discovery, complex molecule analysis, and medical research.

R&D

Interview at BIO 2025 with Juergen Eckhardt

Looking to early-stage companies for innovation, with Juerge...

In an interview at BIO 2025, Bayer's Juergen Eckhardt discusses the importance of external innovation and why his company is prioritising early stage.

R&D

Life Sciences Industry Report - Part 7 cover image

Life Sciences Industry Report - Biologics and Generics

The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.

Newsletters and Deep Dive
digital magazine

Latest News

News

Dismay but little surprise as NICE rejects Alzheimer's drugs

Eli Lilly and Eisai's hopes of making their Alzheimer's disease therapies available to NHS patients in England have been knocked back once again.

News

Gilead's twice-yearly PrEP drug is cleared by FDA

Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?

News

Amid sector disruption, biotech must focus on 'fundamentals'...

The biotech industry in the US is facing a period of deep uncertainty under the Trump administration, but can ride out the storm, says EY.

News

Biogen bids to extend use of Skyclarys to younger patients

Biogen has started a new phase 3 trial that aims to extend the use of its Friedreich's ataxia drug Skyclarys to patients as young as two.

Views & Analysis

Patients

Planning, not panic, as BIO weighs in on US vaccination woes

At BIO 2025, vaccines were top of mind as a result of recent actions by HHS. Speakers addressed news head on, but also explored the larger context.

R&D

Precision, speed, impact: Evolving mass spectrometry for med...

MOBILion's Melissa Sherman explores the evolving role of mass spectrometry in drug discovery, complex molecule analysis, and medical research.

Digital

From pilots to impact: What it really takes to scale GenAI i...

Just a year ago, the GenAI buzz in pharma felt like the start of a gold rush. Leaders greenlit pilots. Teams spun up proof-of-concepts.

Oncology

ASCO 2025: Building a stronger future in cancer care with a ...

From attending key oral sessions, clinical science symposiums and poster presentations to the simple pleasures of chatting with colleagues during coffee breaks, we left the

Deep Dive

Market Access

How Trump's pharma tariffs will hurt industry and patients a...

Market Access

The evolution of real-world evidence

Market Access

The smarter spending playbook: Reviving stagnant pharma prod...

Market Access

From market access to real-world patient access: Closing the...

White Papers & Webinar

Digital

Linear visual illustration of nodes in an arrow shape

Enabling Digitally Enhanced Care for Rare Diseases in Europe

Integrating AI and Connected Care Technologies in Lysosomal Storage Disease Patient Journeys

Market Access

Bridging research and clinical guidelines – interactive stra...

Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.

R&D

Life Sciences Industry Report - Biologics and Generics

The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.

R&D

Life Sciences Industry Report - Rare Disease Space

There are some 7,000 known rare diseases in the world, yet, multiple challenges and unmet needs remain when it comes to therapies for these diseases.

Podcasts & Video

R&D

Precision, speed, impact: Evolving mass spectrometry for med...

MOBILion's Melissa Sherman explores the evolving role of mass spectrometry in drug discovery, complex molecule analysis, and medical research.

R&D

Interview at BIO 2025 with Jeffrey Meckler

Going wide on immune system activation, with Jeffrey Meckler

Indaptus CEO Jeff Meckler discusses his company's unconventional approach to immunotherapy, based on activating a wide swath of the immune system.

R&D

Looking to early-stage companies for innovation, with Juerge...

In an interview at BIO 2025, Bayer's Juergen Eckhardt discusses the importance of external innovation and why his company is prioritising early stage.

Oncology

pharmaphorum podcast Episode 185a - Dr Stacy Lindborg

IMUNON at ASCO 2025: Changing the micro-tumour environment i...

Partner Content

Market Access

Partner Content

EVERSANA expands commercialisation portfolio with OS Therapi...

EVERSANA, a leading provider of global commercial services to the life sciences industry, has announced two strategic partnerships to support the US commercialisation of innovative therapies from O

Digital

Partner Content

The Pharmaceutical Marketing Society and the Chartered Insti...

The PM Society is delighted to announce a new partnership with the CIM to build capability and excellence in marketing in the pharmaceutical industry.

R&D